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Munich, Germany; and {Coagulation Lab, AescuLabor Hamburg, Hamburg, GermanyABSTRACT VonWillebrand Factor (VWF) is a multimeric protein crucial for hemostasis. Under shear flow, it acts as a mecha-
nosensor responding with a size-dependent globule-stretch transition to increasing shear rates. Here, we quantify for the first
time, to our knowledge, the size distribution of recombinant VWF and VWF-eGFP using a multilateral approach that involves
quantitative gel analysis, fluorescence correlation spectroscopy, and total internal reflection fluorescence microscopy. We
find an exponentially decaying size distribution of multimers for recombinant VWF as well as for VWF derived from blood
samples in accordance with the notion of a step-growth polymerization process during VWF biosynthesis. The distribution is
solely described by the extent of polymerization, which was found to be reduced in the case of the pathologically relevant mutant
VWF-IIC. The VWF-specific protease ADAMTS13 systematically shifts the VWF size distribution toward smaller sizes.
This dynamic evolution is monitored using fluorescence correlation spectroscopy and compared to a computer simulation of
a random cleavage process relating ADAMTS13 concentration to the degree of VWF breakdown. Quantitative assessment
of VWF size distribution in terms of an exponential might prove to be useful both as a valuable biophysical characterization
and as a possible disease indicator for clinical applications.INTRODUCTIONThe large plasma glycoprotein von Willebrand Factor
(VWF) is essential for the initiation of blood coagulation
as it promotes adhesion of platelets to the injured vessel
wall as well as platelet aggregation (1,2). It is present in
human blood and the secretory granules of endothelial cells
and platelets. Plasma VWF plays a crucial role in early
hemostasis as it binds rapidly and tightly to collagen when-
ever blood is exposed to injured tissues (3). Remarkably,
VWF is a multimer that consists of several identical subunits
and its function in primary hemostasis strictly correlates
with its multimer size. Even though much research is being
done on its size-dependent functionality, only little is known
about the exact size distribution and its origin. Quantitative
deficiency of plasma VWF causes von Willebrand disease
(VWD) type 1, the most common congenital bleeding disor-
der (1). Although VWD is often caused by a lack of long
multimers, an aberrantly increased activity of VWF due to
larger than normal multimers is assumed to be a pathogenic
factor in thrombotic thrombocytopenic purpura (2,4). The
size-dependent functionality relates to the shear flow-sensi-
tive structure of VWF, which responds to shear by expan-
sion to an elongated form, thereby exposing binding sites
for collagen and the platelet receptor GPIb (5). This process
highly depends on the extent of multimerization of VWF
because smaller multimers are more resistant to shear forces
than larger ones and subsequently binding sites for their
ligands are not as readily exposed (6,7). Consequently, theSubmitted April 3, 2013, and accepted for publication July 24, 2013.
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0006-3495/13/09/1208/9 $2.00size of the multimeric VWF is a critical factor for VWF’s
functionality and the question arises, which size distribution
is produced by VWF biosynthesis and how it is controlled in
homeostasis. In polymer science, the problem of polymer
size distribution has been addressed by the seminal work
of Paul Flory in 1936, in which he calculated the exact
size distribution of polymers based on the model of step-
growth polymerization reaction (8). He showed that a
theoretical prediction of a multimer size distribution is
possible if the mechanism and the kinetics of the synthesis
reaction are known. Vice versa, the size distribution pro-
vides clues with respect to the polymerization mechanism.
VWF is expressed as a proprotein (Fig. 1 A), which is
translocated into the endoplasmatic reticulum, where it
dimerizes via intermonomer disulfide bonds in the
C-terminal domain (Fig. 1 B). The dimers with a molecular
mass of 500 kDa represent the repeating unit of the VWF
multimer. They are transported from the endoplasmatic
reticulum (pH z 7.4) to the Golgi (pH z 6.2). This is the
place where multimerization occurs by formation of linear
multimers via interchain disulfide bonds at the N-terminal
resulting in multimeric VWF with molecular masses of up
to > 40.000 kDa (Fig. 1 C) (9–11). In this process, VWF
propeptide acts as an oxidoreductase to promote VWF
multimerization (12–14). The propeptide is then cleaved
for separate secretion (15,16). After multimerization,
VWF is either secreted constitutively to the plasma or stored
in Weibel-Palade bodies and released upon certain stimuli
(e.g., thrombin, plasmin, fibrin) without further multimeri-
zation taking place in the plasma (17). For a postsecretion
size regulation, circulating VWF undergoes cleavage byhttp://dx.doi.org/10.1016/j.bpj.2013.07.037
FIGURE 1 Schematic representation of plasma VWF size regulation. (A)
VWF is synthesized by endothelial cells and megakaryocytes and originates
from a 360 kDa monomer. (B) Monomeric VWF is transported to the endo-
plasmic reticulum where it is dimerized through intermonomer disulfide
bonds. (C) Multimerization takes place in the Golgi apparatus, where the
dimers form multimers with sizes ranging from 500 to 40.000 kDa, which
are then secreted to the blood plasma. (D) Size control in plasma is provided
by the protease ADAMTS13. No further multimerization occurs after
secretion to the plasma.
Exponential Size Distribution of VWF 1209the specific metalloprotease ADAMTS13, a disintegrin and
metalloproteinase with a thrombospondin type 1 motif,
member 13 (Fig. 1 D) (18). As known from bleeding disor-
ders, defects in VWF multimer synthesis or size regulation
have fundamental implications in hemostasis and exhibit
defined patterns in VWF gel electrophoresis. Yet, the size
distribution of VWF and its molecular causation has not
been quantitatively studied so far.
Here, we investigate the size distribution of VWF using
fluorescence correlation spectroscopy (FCS), quantitative
gel analysis, and total internal reflection fluorescence
microscopy (TIRFM). TIRFM allows for direct imaging
of recombinant VWF-eGFP multimers including the assess-
ment of VWF size by intensity analysis. Gel analysis is
widely accepted in VWF diagnostics for screening patient
samples for diseases. FCS measures the hydrodynamic
size of fluorescently labeled species in solution. In contrast
to gel analysis and TIRFM, FCS allows for measurements of
fluorescent VWF-eGFP in blood plasma and is therefore
well suited for VWF analysis in its native environment.
We compare the size distribution of recombinant VWFand VWF-eGFP and its disease-related mutant VWF 2A
(IIC), which is characterized by an increased concentration
of dimers (19,20). We show that after secretion from VWF
producing cells, VWF has an exponential size distribution in
both healthy and pathologic form. The physiological and
pathological distributions are distinct in the extent of
polymerization characterizing the distribution. We also
show that proteolytic cleavage by ADAMTS13 leads to non-
exponential distributions that shift with time allowing for
in situ monitoring of VWF cleavage under blood plasma
conditions.MATERIALS AND METHODS
Production of recombinant VWF
The recombinant fusion protein rVWF-eGFP was expressed and purified
separately in its monomer, dimer, and multimer form as described in detail
in the following:
Cloning of a VWF-enhanced green fluorescent protein
(EGFP) Plasmid
From the plasmid pIRESneo2-vWF (Takara Bio Europe/Clontech, Saint-
Germain-en-Laye, France) the stop codon was eliminated and an EcoRI
restriction site was introduced. The EGFP sequence was cut out from the
plasmid pEGFP-N2 (Takara Bio Europe/Clontech) by EcoRI and NotI
and inserted into plasmid pIRESneo2 by using its EcoRI/NotI restriction
sites (pIRESneo2-EGFP). Subsequently, VWF-cDNA from plasmid
pIRESneo2-VWF lacking the stop codon was cut out by EcoRI and cloned
into pIRESneo2-EGFP (pIRESneo2-VWF-EGFP).
pIRESneo2-VWF-EGFP was then used to produce three mutant
constructs:
1) pIRESneo2-vWF-delPro-EGFP with the retained signal peptide
sequence and the first three codons of the VWF propeptide but lacking
the rest of the propeptide corresponding to codons 26–763 (delT26-
R763). Expression of this construct will result in VWF monomers that
assemble into carboxy-terminal dimers but not into larger multimers.
2) pIRESneo2-vWF-delPro/C2771R-EGFP, which was produced by
in vitro-mutagenesis of construct 1), by exchanging codon 2771
for cysteine against the naturally occurring mutation to arginine
(p.C2771R). Expression of this construct results in VWF monomers
only, because p.C2771R causes a severe dimerization defect (R. Schnep-
penheim, unpublished) in addition to the multimerization defect of the
VWF-delPro construct 1.
3) PIRESneo2-vWF-C1099Y-EGFP, which was produced by in vitro-muta-
genesis of wild-type pIRESneo2-VWF-EGFP, by exchanging codon
1099 for cysteine against the naturally occurring mutation to tyrosine
(p.C1099Y). Expression of this mutant results in near normal quantita-
tive expression of mutant VWF, however, lacking large and medium
sized VWF multimers as in the phenotype IIC of VWD type 2A.
Generation of stable cell lines constitutively secreting VWF
Transfection of 293 cells was carried out as described previously (21). 48 h
after transfection cells were trypsinized and grown until confluence in
Dulbecco’s modified Eagle’s medium buffer containing 10% fetal bovine
serum and G418 at 500 mg/ml for selection. After further propagation of
an aliquot of the stable cell line until 70–80% confluence, cell culture
medium was changed to OPTIPRO-SFM medium for serum-free expres-
sion. Cell culture medium was harvested after 72 h and concentrated by
Amicon Ultrafree (MWCO 100000 DA) if necessary.Biophysical Journal 105(5) 1208–1216
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The patient samples were sent to our laboratory for the evaluation of VWF
multimers and subtyping of the already known VWD. Informed consent
was obtained from all subjects.Quantitative gel analysis
VWF multimer analysis was carried out in sodium dodecyl sulfate agarose
gels combined with immunoblotting and luminescence visualization. The
luminescent blot was stored on electronic media using photo imaging
(FluorChem8000; Alpha Innotech, San Leandro, CA) (22). VWFmultimers
were separated via gel electrophoresis and visualized by detecting their
luminescent signal. Electrophoretic bands were visualized by means of
luminescent immunoblotting. Thereby, intensities were obtained by
labeling the proteins with horseradish peroxidase-conjugated antibodies
that cleave a chemiluminescent agent producing luminescence that is
proportional to the amount of protein (23).
The multimer patterns of rVWF and rVWF-eGFP are taken from
different gels, which were recorded on different days. Therefore, the run
times vary from sample to sample. As the run times are not used for data
analysis this does not have any influence on the analyzed data.FCS
FCS detects the dynamics of fluorescently labeled molecules diffusing in
and out of a confocal volume (24–28) and can be applied to multicom-
ponent systems with different fluorescent species (29). It can be used for
measurements in crowded media like blood plasma, thus enabling the study
of molecules in their native environment (30). This ensures that the inves-
tigated molecules keep their natural properties, because these often change
in bulk fluids acting as solvents and thereby reducing effects such as
aggregation. FCS data analysis is described in detail in the Supporting
Material.
For FCS measurements, an Axiovert 200 microscope with a ConfoCor 2
unit (Carl Zeiss, Jena, Germany) equipped with a 40 (NA ¼ 1.2) water
immersion apochromat objective (Carl Zeiss) was used. An argon laser
(488 nm) was used for illumination. Samples were measured in eight-
well LabTek I chamber slides (Nunc, Rochester, NY). All measurements
were performed in 5 mM Tris-HCl, pH 8.0 with 1.5 M urea at a temperature
of 37C controlled by an ibidi heating stage (ibidi GmbH, Martinsried,
Germany). At this urea concentration, VWF can be conceived as a semi-
flexible polymer as urea stretches it without affecting its basic structure.
These conditions are widely used for VWF analysis if measurements
with the stretched polymer have to be performed without shear flow
(4,31). eGFP functionality was proved to be functional under this buffer
condition in agreement with Alkaabi et al. (32). Measurements were per-
formed for 10  60 s (eGFP, monomer and dimer) and 20  6 min
(rVWF; rVWF-IIC). To ensure optimal fluctuation detection for multicom-
ponent analysis, we chose long measurement times to obtain sufficient
statistics while keeping concentrations low (20 nM for all samples).
Correlation was performed using ConfoCor 2 software. For FCS data anal-
ysis, a Labview routine was implemented.TIRFM
TIRFM is a suitable technique for imaging fluorescent molecules on a trans-
parent substrate with single molecule resolution (33,34). The technique
uses the evanescent field of a totally internal reflected laser beam exciting
only fluorophores above the substrate surface within typically 100 nm. This
provides a high signal/noise ratio of the collected fluorescence and is
therefore well suited for direct imaging of fluorescent molecules.
For TIRFM measurements, rVWF was immobilized on epoxy silane-
coated glass slides and imaged using the TIRFM setup presented in (35).Biophysical Journal 105(5) 1208–1216For excitation in the total internal reflection mode, a 473 nm laser (iBeam
smart, TOPTICA, Gra¨felfing, Germany) was used at a power of 0.4 mW.
The corresponding filter set consisted of a Chroma z 470/10, a Chroma z
470 RDC, and a Chroma HQ 525/50 (Chroma Technology GmbH, Olching,
Germany). The emitted light signal was detected by a back-illuminated
EMCCD camera (DU-860D, Andor, Belfast, Ireland). The EMCCD chip
was operated at a temperature of 90C and the electron multiplication
gain was set to 300-fold. 3000 frames (21  21 mm2) were taken per image
sequence with a recording rate of 10 frames/s. All measurements were
carried out in phosphate buffered saline. To minimize eGFP bleaching
before the actual measurement, all adjustment procedures were carried
out at low laser power (0.1 mW).
Data analysis was obtained with a step detection algorithm. As the
routine cannot distinguish between on- and off-steps and fails in detecting
steps that occur within a very short time slot, the obtained step number was
corrected by eye for blinking and missed steps.Proteolysis of full-length rVWF by ADAMTS13
Cleavage of recombinant VWF-eGFP by ADAMTS13 was achieved as
reported in Pruss et al. (36). Cleaved samples were stored at 80C until
multimer analysis was performed.RESULTS
Quantitative gel analysis of rVWF
Gel analysis is the most frequently used technique for VWF
multimer analysis (22,23,36). By quantitative analysis of the
intensity profiles obtained by antibody staining in gels
(Fig. 2, A,B and C,D, respectively) we yield the size distri-
bution of VWF, which in a semilogarithmic plot shows good
agreement with an exponential (Fig. 2, E and F). Hereby we
assume that antibody staining is proportional to the number
of dimers in the VWF multimer. The gels were evaluated
using luminescent immunoblotting implying that the
measured luminescent signal intensities in each band reflect
the number of antibody labels (Fig. 2, C and D). The signal
was normalized by the number of dimers i corresponding to
the size of the multimers in the respective band. These
normalized intensities correspond to the molar distribution
function and were plotted in a semilogarithmic diagram
versus the multimer size given in number of dimers i
(Fig. 2, E and F). We took gel data from both wild-type
rVWF and rVWF-IIC and their eGFP fusion analogs
(Fig. 2 A) as well as from VWF of normal plasma VWF-
NP and patient plasma VWF-IIC (Fig. 2 B). For rVWF,
clearly an exponential decay is found. One possible mecha-
nistic explanation for such an exponential decay is the Flory
theory of linear condensation polymers (8) that describes a
step-growth polymerization process taking place in an
enclosed reactor by the intermolecular reaction of bifunc-
tional compounds (for details, see the Supporting Material).
It predicts an exponential size distribution for step-growth
polymerization resulting in a molar fraction of i-mers
containing i subunits (8)
Ni
N
¼ ð1 pÞpi1: (1)
FIGURE 2 Quantitative gel analysis of recombinant and blood plasma
VWF. (A) Multimer patterns of recombinant VWF distributions showing
a ladder of multimers. (B) Multimer patterns of VWF distribution of normal
plasma and of a patient with von Willebrand disease type IIC. (C and D)
Densitogram intensity is plotted versus multimer size in terms of dimer
number i. (E) Fits of normalized data show no significant difference in
size distribution between rVWF (gray squares) and fluorescent rVWF-
eGFP (black squares), stressing that the recombinant distribution with fused
eGFP exhibits a normal multimerization behavior. Best fits to the gel data
are obtained using an exponential function N(i) ¼ N1pi-1 with an extent
of polymerization of p ¼ 0.70 (black dotted line). For pathological
rVWF-IIC (green triangles), a reduced extent of polymerization of p ¼
0.36 (dark green dotted line) for rVWF-IIC and p ¼ 0.22 (green dotted
line) for rVWF-IIC-eGFP is obtained. (F) Both plasma samples show like-
wise an exponential decay with a decreased p ¼ 0.66 for pathological
VWF-IIC (VWF-NP: p ¼ 0.78). We observe a small, systematic deviation
for large multimer sizes due to enzymatic cleavage in the plasma.
Exponential Size Distribution of VWF 1211Here, Ni and N represent the number of i-mers and the total
number of VWF molecules, respectively. p indicates the
extent of polymerization, i.e., the number of polymerized
subunits to the total number of subunits, N. We assume
that VWF multimerization complies with the step-growth
polymerization model insofar as the formation of disulfide
bonds can be assumed to be independent of size and the re-
action volume is finite, which is a reasonable assumption
considering the fact that multimerization occurs in the Golgi
Apparatus only. Fitting the measured size distribution by the
exponential function N(i) ¼ N1pi-1 yields an extent of poly-
merization of p ¼ 0.70 5 0.02 for rVWF. N1 is a constant
fitting parameter that contains information about the number
of dimers available for polymerization (for details, see the
Supporting Material). p describes the slope of the size distri-bution: high values of p indicate a slowly decaying size dis-
tribution with long multimers being more abundant,
whereas small values of p indicate a steep decay with only
a small amount of long multimers. The same exponential
decay as for rVWF is found for rVWF-eGFP (black
squares), showing that the shape of the distribution does
not change significantly when fusing eGFP to VWF. The
recombinant VWF-eGFP construct is therefore well suited
for further studies employing fluorescence microscopy.
The pathological rVWF-IIC appears only in a few bands
of short sizes due to its lack of large multimers. Fitting
yields an exponential, as for physiological VWF, yet with
an extent of polymerization p ¼ 0.36 5 0.01 for rVWF-
IIC (dark green) and p ¼ 0.22 5 0.01 for rVWF-IIC-
eGFP (green).
Physiological VWF derived from blood samples also
exhibits an exponential decrease (Fig. 2 F) with an extent
of polymerization p ¼ 0.78 5 0.02 for normal patients.
However, the distribution function seems to exhibit a slight,
but systematic deviation underrepresenting the larger frac-
tion. This deviation can be attributed to ADAMTS13-
induced cleavage that occurs in plasma and is depicted in
the gels by the two satellite bands flanking the main bands
that are known to be the products of proteolysis. Patholog-
ical VWF-IIC from plasma of patients suffering from von
Willebrand disease type IIC shows an extent of polymeriza-
tion p ¼ 0.66 5 0.01.FCS single-component analysis of rVWF
FCS allows for size measurements of fluorescently labeled
VWF in solution and is in principle capable to resolve mul-
tiple species with varying diffusion properties. We find that
the measured FCS autocorrelation functions of recombinant
VWF-eGFP are consistent with an exponential size distribu-
tion. First, we investigate recombinant VWF-eGFP (rVWF)
monomer and dimer. A single-component analysis provides
diffusion times (diffusion coefficients) of tD ¼ 322 ms (D ¼
31.9 mm2/s) for the monomer and tD ¼ 447 ms (D ¼
19.5 mm2/s) for the dimer (Fig. 3 A). Fig. 3 A also shows
purified eGFP as a control. The eGFP diffusion time of
tD ¼ 90 ms is in agreement with previous results (37).
Because VWF is a rather elongated protein (11) a crude
approximation of the VWF monomer and the VWF dimer
as cylinders with the same diameter and twice the length
for the dimer is reasonable. With these assumptions, the
measured diffusion coefficients correspond to a cylinder
3 nm in diameter and 85.3 nm (dimer) and 42.7 nm
(monomer) in length (for details, see the Supporting
Material). This is in accordance with experiments per-
formed by tapping mode atomic force microscopy (38)
and electron microscopy measurements (11).
The single-component analysis can also be used as a first
approximation of the full VWF distribution. Because it
averages over all the species within the sample, it cannotBiophysical Journal 105(5) 1208–1216
FIGURE 3 FCS measurements of recombinant VWF distributions and
their building blocks. (A) Single-component fits of eGFP (light blue),
rVWF monomer (dark blue), and rVWF dimer (purple) give correlation
times tD of 90 ms, 322 ms, and 447 ms. Assuming a cylindrical shape for
the dimer, the corresponding diffusion coefficient D¼ 19.5 mm2/s character-
izes a cylinder with length l ¼ 85.3 nm and d ¼ 3 nm. A clear shift toward
longer diffusion times can be seen for the multimer distribution rVWF
(black). (B) Single-component analysis was used as a first estimate of the
autocorrelation function of physiological rVWF (black). A clear shift can
be seen for pathological rVWF-IIC (green) that allows distinguishing
between normal and abnormal conditions. Average diffusion times of tD ¼
22445 515 ms (rVWF) and tD ¼ 7125 22 ms (rVWF-IIC) are obtained.
FIGURE 4 Multimer analysis of rVWF using FCS. (A) Multicomponent
fit (red dotted line) of the autocorrelation function of physiological rVWF
1212 Lippok et al.reflect the different species within the VWF size distribu-
tion. Thus, single-component analysis is not able to provide
the actual size distribution N(i). However, it provides an
average VWF size and is suited to rapidly pinpoint differ-
ences between the physiological distribution of rVWF and
of the pathological distribution rVWF-IIC (Fig. 3 B)
showing an average diffusion time of tD ¼ 2244 5
515 ms (black line) for physiological and tD ¼ 712 5 22
ms (green line) for pathological rVWF. For rVWF, the diffu-
sion time is in good agreement with measurements per-
formed by Torres et al. (39) who detected an average
diffusion time of 2.0–3.5 ms for VWF-NP bound to fluores-
cently labeled antibodies. For rVWF-IIC, the lack of large
multimers explains the shift to shorter diffusion times in
our measurements. Although this single-component anal-
ysis does not contain quantitative information about the
size distribution of VWF, it is clearly sufficient to distin-
guish between the physiological and the investigated patho-
logical VWF distribution (Fig. 3 B).(black line) leads to a size distribution that decays with the base p ¼ 0.64.
Furthermore, the single-component analysis (gray dashed line) fits the
distribution well, yielding an average multimer size of i ¼ 6.3 5 1.4
dimers. (B) With the multicomponent fit (red dotted line) for the patholog-
ical distribution rVWF-IIC (green line), the base is determined to be p ¼
0.18, indicating the lack of large VWF multimers. Single-component fit
(gray dashed line) infers an average multimer size of i ¼ 2.05 0.1 dimers.FCS multicomponent analysis of rVWF
To examine the nature of the VWF size distribution a
multimer analysis was applied (Fig. 4) and found to be
consistent with the exponential size distribution measured
with quantitative gel analysis. The multimer analysis allows
to compare the autocorrelation function expected for a given
size distribution N(i) with the experimental autocorrelation
curve (see the Supporting Material, S1). Several distribution
functions were tested forN(i). Best results are achieved using
an exponential function N(i) ¼ N1pi-1 in agreement with the
data obtained with quantitative gel analysis. The base is
found to be p ¼ 0.64 for physiological rVWF (Fig. 4 A)
and p ¼ 0.18 for pathological rVWF-IIC (Fig. 4 B).Biophysical Journal 105(5) 1208–1216The best fit to the exponential distribution shows a small
improvement over the initial single component analysis
(Fig. 4). The fact that the multicomponent analysis is
close to a single component fit is explained by the fact
that the FCS autocorrelation function weights each mole-
cule with its squared brightness (see the Supporting Mate-
rial). For rVWF-eGFP the brightness scales with the
number of dimers i, the resulting weighted size distribution
Exponential Size Distribution of VWF 1213is N0(i) ¼ i2 N(i), which exhibits a sharp maximum at the
average multimer size i ¼ 4.7. Due to the narrow weighted
distribution function, the multicomponent fit appears to be
close to the fit of a single species. The average multimer
size is in good agreement with the average multimer size ob-
tained with single-component analysis that yields i ¼ 6.35
1.3 for rVWF (for details see the Supporting Material S1).
For the mutant rVWF-IIC with p ¼ 0.18, an average multi-
mer size of i ¼ 1.5 is calculated compared to i ¼ 2.05 0.1
measured with the single-component fit. However, it is
important to note that the proper multicomponent analysis
using the proposed exponential size distribution N(i) de-
scribes the measured autocorrelation function the best
within the experimental accuracy.FIGURE 5 Direct imaging of rVWF using TIRFM. (A) TIRFM image of
VWFmultimers immobilized on a glass surface. The multimer size is deter-
mined by counting eGFP bleaching steps as each rVWFmonomer is labeled
with one eGFP. The intensity-time traces of the two highlighted molecules
represent an 8-mer (B) and a dimer (C). The positions of the counted steps
are indicated with arrows. (D) The relative frequency for detecting a certain
number of steps in the intensity trace is shown as a bar chart. Size distribu-
tion analysis of N(i) (black squares) yields, in good agreement with the
results from quantitative gel analysis and FCS, an exponentially decaying
size distribution N(i) ¼ N1pi-1 (red dots) with the base p ¼ 0.29.Direct imaging of VWF with TIRFM
The data presented so far reveals an exponential size distri-
bution of VWF. Using TIRFM, we confirmed these results
by direct imaging. Under continuous excitation, the fluores-
cence signal of rVWF-eGFP was observed to decrease in
discrete steps over time. As described in (40) and explained
in detail in the Supporting Material S3, the number of
bleaching steps can be taken as a measure for the number
of eGFP-tagged VWF monomers. Counting bleaching steps
therefore provides a means for analyzing the VWF size
distribution. Measurements of an rVWF dimer sample
proved that this analysis method is indeed suitable for our
samples (see the Supporting Material S3).
For localizing the rVWF multimers, an average image of
the first 100 frames was calculated (Fig. 5 A) and regions of
interest were selected. Bleaching steps in the intensity-time
traces of these regions were identified with the step detec-
tion algorithm described in (41) (Fig. 5, B and C). The rela-
tive frequency for detecting a certain number of steps was
plotted versus the number of steps (Fig. 5 D) and each
step number was assigned to a certain multimer size. As
we count the multimer size in number of dimers i but the
bleaching steps scale with the number of monomers, two
bleaching steps add up to an increase of one in the multimer
size. Odd numbers of bleaching steps were round up to the
next even number. The thereby obtained size distribution
N(i) was plotted versus the multimer size in number of
dimers i. Fitting yields an exponentially decaying size distri-
bution N(i) ¼ N1pi-1 with a base p ¼ 0.29 (Fig. 5 D),
convincingly confirming the findings from quantitative gel
analysis and FCS.Effect of ADAMTS13 cleavage on VWF size
distribution
The VWF size distribution is after secretion into the blood
plasma dynamically controlled by the protease ADAMTS13
(Fig. 1 D) with defects in ADAMTS13 activity resulting in
unusually large VWF that cause thrombotic thrombocyto-penic purpura. We investigated this time-dependent evolu-
tion of the VWF size distribution with FCS and found
systematic shifts to smaller multimer sizes that are no
longer exponentially distributed. Various concentrations of
ADAMTS13 were used to visualize different cleavage
states. rVWF concentrated to 65% of normal plasma con-
centration (0.65 units/ml) was digested by 0.12, 0.25, and
1.00 units/ml ADAMTS13. As expected, the cleavage due
to ADAMTS13 shifts the autocorrelation curves to higher
particle numbers (lower amplitude) and shorter diffusion
times (steeper decay). It is not possible to describe these
autocorrelation curves with a multicomponent analysis
with an exponentially decaying size distribution N(i), indi-
cating that the cleavage changes the shape of the distribu-
tion. Yet, using single-component analysis it is possible to
extract average diffusion times of tD ¼ 1045 ms, 813 ms,
and 617 ms (0.12, 0.25 and 1.00 units/ml ADAMTS13)
(Fig. 6 A). We find an exponential dependence of the
average multimer size in terms of dimer number i on theBiophysical Journal 105(5) 1208–1216
FIGURE 6 Multimer analysis after ADAMTS13-induced proteolytic
cleavage. (A) Varying concentrations of ADAMTS13 are used to visualize
different cleavage states. Correlation curves of rVWF distribution are
shifted toward lower correlation times and higher particle concentrations
(lower G(0)) with increasing protease concentration. (B) Single-component
analysis indicates an exponential decay of the average multimer sizes
with increasing ADAMTS13 concentration. (C) Simulation of a random
cleavage process shows the changes in the size distribution due to
ADAMTS13 cleavage. (D) Average multimer sizes decrease exponentially
with an increasing number of cleavage steps per molecule. Comparing the
decay constant in (B) and (D), ~0.1 units/ml ADAMTS13 and one cleavage
step per molecule lead to a similar effect on the average multimer size.
1214 Lippok et al.ADAMTS13 concentration with i ¼ 4.5, 2.6, and 1.2, corre-
sponding to 0.12, 0.25, and 1.00 units/ml concentration of
ADAMTS13 (Fig. 6 B).
To get an estimate of the size distribution in the presence
of ADAMTS13, the cleavage process was simulated based
on a model that assumes random cleavage sites combined
with equal cleavage probability for all multimer sizes
(Fig. 6 C). Starting with the measured exponentially shaped
multimer distribution, each iteration cuts each multimer
once at a random site. For each iteration, the average multi-
mer size of the generated size distribution is calculated and
plotted against the number of cleavage steps (Fig. 6 D).
Comparison of experiment and simulation (Fig. 6, C and
D), shows that the average multimer size scales exponen-
tially with the number of cleavages of each molecule, with
~0.1 units/ml ADAMTS13 and one cleavage step resulting
in the same average multimer size. This means that a 0.1
units/ml ADAMTS13 concentration is necessary to cleave
each molecule of a 0.65 units/ml VWF concentration once
within 5 h.DISCUSSION
In this article, we found independent evidence that the size
of recombinant VWF is exponentially distributed. FirstBiophysical Journal 105(5) 1208–1216quantitative gel analysis of VWF based on antibody staining
indicates an exponential size distribution, second a FCS
multicomponent analysis of recombinant VWF-eGFP
proves consistent with the proposed distribution function,
and finally the frequency distribution obtained from direct
single molecule fluorescence imaging yields an exponential
dependence for the first five VWF-eGFP multimer sizes. An
exponential size distribution as such is not unexpected and
well known for both equilibrium polymers (42) and linear
condensation polymers (8). An equilibrium polymer forms
by reversible association of subunits with mutual binding
constant affinity. Prominent examples for equilibrium poly-
mers are actin, microtubulin, and other cytoskeleton fila-
ments (43). Linear condensation polymers are formed by
irreversible growth mechanisms. It is well established that
VWF is a covalently linked multimer as the VWF multime-
rization occurs via formation of disulfide bonds. Further-
more, it is understood that the VWF multimerization takes
place in the Golgi, where the propeptide of VWF itself
acts as oxidoreductase, thereby facilitating disulfide bond
formation that allows VWF to polymerize in this compart-
ment (12–14). An exponential size distribution results if
the reactivity of subunits is independent of the segment
size and takes place in a finite compartment. In this case,
the molar fraction of segments containing i subunits is given
by Eq. 1. The distribution is fully determined by a single
parameter, the extent of polymerization, p. This extent of
polymerization is limited both by the reaction rate of the
VWF molecules to each other and by the reaction time,
which is determined by the time the VWF remains in the
Golgi. We find that the fraction of polymerized dimers is
prVWF ¼ 0.70 5 0.02 for rVWF and prVWF-IIC ¼ 0.22 5
0.01 in case of the pathological form rVWF-IIC. It is note-
worthy that for the disease mutant VWF-IIC, the exponen-
tially decaying size distribution is maintained indicating
that the mechanism of biosynthesis is the same. As
aberrances in the size distribution of VWF-IIC are caused
by mutations in the VWF propeptide that prevent multime-
rization in the Golgi (44), a decreased reaction rate can be
assumed and explains the lower extent of polymerization.
The fact that the exponential VWF size distribution is in
accordance with a step-growth reaction mechanism allows
the quantification of a VWF distribution by a single param-
eter. Knowing the extent of polymerization p yields the
entire range of multimers. An interesting finding is the
fact that the extent of polymerization is in general fairly
low with far less long multimers being formed than hitherto
expected. For the physiological distribution rVWF, 30% of
VWF dimers remain as non-polymeric species. Multimers
consisting of five or more dimers account for only 24% of
the total number of VWF molecules whereas multimers
containing 10 or more dimers represent just 4%. Hence,
the polymeric form of VWF that is supposed to be the one
most relevant for VWF function is a minority species
of VWF. Secondly, as characteristic for the base of an
Exponential Size Distribution of VWF 1215exponential function, already small changes in p have a
strong leverage on the multimer distribution and conse-
quently a detrimental impact on the physiological state. A
loss of 25% in the extent of polymerization reduces the
number of 10mers by a factor of 100.
The size distribution of VWF is changed upon secretion
to the blood plasma by ADAMTS13-induced cleavage.
We used rVWF to mimic this cleavage process. Varied
cleavage states represented by different concentrations of
ADAMTS13 can be clearly distinguished from uncleaved
rVWF. The exponentially shaped size distribution is not
maintained during cleavage. Simulation of a random cleav-
age process allows us to relate the ADAMTS13 concentra-
tion to a certain number of cleavage steps. We show that
cleavage with 0.1 units/ml ADAMTS13 concentration under
partly denaturing condition in urea has the same effect on
the average multimer size as cutting each VWF molecule
once at a random site. In blood plasma, ADAMTS13-
induced cleavage is assumed to require shear-induced
stretching of VWF. We find that the size distribution of
healthy patients exhibits almost the same exponential size
dependence as recombinantly expressed VWF. Small devia-
tions at larger size fractions could be indicative of extracel-
lular ADAMTS13 activity in blood flow. Interestingly, the
size distribution of patients exhibiting von Willebrand
disease type IIC showed less deviation from the normal
case as predicted from the recombinant expressed VWF-
IIC. It must be assumed that the deficiency in the extent
of polymerization is partly compensated, possibly by
VWF expelled from Weibel-Palade bodies. Plasma VWF
is essential for the initiation of blood coagulation but is
immediately joined by VWF stored in the granules of endo-
thelium cells (Weibel-Palade bodies) at the beginning of
hemostasis so that long VWF multimers can be provided
whenever needed.
From a measurement technique point of view, we showed
that FCS is capable of following the evolution of VWF size
distribution under blood plasma conditions. This opens up
the possibility to use recombinant VWF-eGFP in combina-
tion with FCS as a diagnostic assay for ADAMTS13 activity
in hematology. Moreover, FCS has the capability to use
shear forces during measurement. Therefore, experiments
with urea as a stretcher could become redundant and be
replaced by measurements under shear flow in situ.CONCLUSION
In this work, we reported on the exponential size distribu-
tion of recombinant and physiological VWF multimers.
We found evidence that the exponential distribution is the
generic outcome of VWF biosynthesis as disease-related
VWF mutant VWF-IIC also exhibits an exponential size
distribution, albeit with a smaller extent of polymerization.
In light of this finding, we hypothesize that the disease-
related mutation type IIC affects the polymerization reac-tion. We show that FCS allows for monitoring the change
in VWF-eGFP size distribution under blood plasma condi-
tions over time. In particular, ADAMTS13 activity was
measured and it was shown that the decreasing average
VWF size is in agreement with the expected evolution of
an exponential distribution under random cleavage. We
believe that the extent of polymerization, describing the
size distribution of VWF, provides a valuable indicator in
VWF-related disease diagnostics and that FCS proves
valuable as a quantitative tool to follow the evolution of
VWF size distribution in vitro over time.SUPPORTING MATERIAL
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